165 related articles for article (PubMed ID: 24241205)
1. Immunovirotherapy for glioblastoma.
Ning J; Wakimoto H; Rabkin SD
Cell Cycle; 2014; 13(2):175-6. PubMed ID: 24241205
[No Abstract] [Full Text] [Related]
2. Viral therapy of glioblastoma multiforme.
Whitley RJ; Markert JM
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11672-3. PubMed ID: 23836634
[No Abstract] [Full Text] [Related]
3. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.
Cheema TA; Wakimoto H; Fecci PE; Ning J; Kuroda T; Jeyaretna DS; Martuza RL; Rabkin SD
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):12006-11. PubMed ID: 23754388
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Saha D; Martuza RL; Rabkin SD
Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
[TBL] [Abstract][Full Text] [Related]
5. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.
Alessandrini F; Menotti L; Avitabile E; Appolloni I; Ceresa D; Marubbi D; Campadelli-Fiume G; Malatesta P
Oncogene; 2019 Jun; 38(23):4467-4479. PubMed ID: 30755732
[TBL] [Abstract][Full Text] [Related]
6. Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.
Estevez-Ordonez D; Chagoya G; Salehani A; Atchley TJ; Laskay NMB; Parr MS; Elsayed GA; Mahavadi AK; Rahm SP; Friedman GK; Markert JM
Neurosurg Clin N Am; 2021 Apr; 32(2):265-281. PubMed ID: 33781507
[TBL] [Abstract][Full Text] [Related]
7. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
[TBL] [Abstract][Full Text] [Related]
8. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
Menotti L; Avitabile E
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
[TBL] [Abstract][Full Text] [Related]
9. RE: stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Krause MN; Sancho-Martinez I; Izpisua Belmonte JC
J Natl Cancer Inst; 2015 Jan; 107(1):368. PubMed ID: 25473104
[No Abstract] [Full Text] [Related]
10. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
Saha D; Martuza RL; Rabkin SD
Cancer Cell; 2017 Aug; 32(2):253-267.e5. PubMed ID: 28810147
[TBL] [Abstract][Full Text] [Related]
11. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.
Bernstock JD; Hoffman SE; Chen JA; Gupta S; Kappel AD; Smith TR; Chiocca EA
Viruses; 2021 Jun; 13(6):. PubMed ID: 34204248
[TBL] [Abstract][Full Text] [Related]
12. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
13. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
16. How to get from here to there: tracking down invasive glioma cells.
Fine HA
J Natl Cancer Inst; 2014 Jun; 106(6):dju120. PubMed ID: 24838836
[No Abstract] [Full Text] [Related]
17. Intraventricular immunovirotherapy; a translational step forward.
Bernstock JD; Blitz S; Kang KD; Friedman GK
Oncotarget; 2023 Jan; 14():40-43. PubMed ID: 36634220
[TBL] [Abstract][Full Text] [Related]
18. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
Uchida H; Marzulli M; Nakano K; Goins WF; Chan J; Hong CS; Mazzacurati L; Yoo JY; Haseley A; Nakashima H; Baek H; Kwon H; Kumagai I; Kuroki M; Kaur B; Chiocca EA; Grandi P; Cohen JB; Glorioso JC
Mol Ther; 2013 Mar; 21(3):561-9. PubMed ID: 23070115
[TBL] [Abstract][Full Text] [Related]
20. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
